Business
BlinkLab Launches Pivotal US FDA Trial for AI Smartphone Autism Diagnostic
Landmark US FDA Clinical Trial | First Participant Enrolled in Autism Diagnostic Study Across 10 Elite American Hospitals BlinkLab Ltd (ASX:BB1) PRINCETON,
About this update from Blinklab Limited
[{"type":"text","content":" Landmark US FDA Clinical Trial | First Participant Enrolled in Autism Diagnostic Study Across 10 Elite American Hospitals BlinkLab Ltd (ASX:BB1)With a clear pathway toward FDA submission and strong execution underway, we believe BlinkLab is well positioned to transform how autism is assessed in clinical practice.”— BlinkLab CEO and Managing Director, Dr Henk-Jan BoelePRINCETON, NJ, UNITED STATES, March 23, 2026 /EINPresswire.com/ -- A Western Australia-headquartered med tech company developing AI-powered, smartphone-based diagnostic technology for autism spectrum disorder, today announced the commencement of its pivotal validation study to support its planned US Food and Drug Administration (FDA) 510(k) submission, with the first child participant now enrolled and tested using BlinkLab's flagship diagnostic platform, BlinkLab Dx1. The milestone marks the opening of the most significant clinical programme in the company's history, and represents a major advance in the global effort to make autism diagnosis faster, more objective, and more accessible to the millions of families currently facing multi-year waits for a formal assessment. BlinkLab CEO and Managing Director, Dr Henk-Jan Boele, commented: “We are excited to initiate this next phase of our FDA 510(k) regulatory program. It marks what I believe is the most important milestone for BlinkLab to date, following years of focused development, extensive testing, optimisation of our tech, close collaboration and meetings with the FDA, and securing IRB approvals to support clinical execution. With a clear pathway toward FDA submission and strong execution underway, we believe BlinkLab is well positioned to transform how autism is assessed in clinical practice.” The Autism Diagnosis Problem — and Why It Matters Autism spectrum disorder (ASD) affects approximately 1 in 31 children in the United States, according to data published by the Centers for Disease Control and Prevention in May 2025. Despite this prevalence, access to timely, accurate diagnosis remains critically constrained. Families in the US face an average wait of 18 to 24 months for formal assessment. Approximately 21% of US autism clinics are currently unable to accept new referrals due to workforce shortages and overwhelming demand. The current diagnostic gold standard, the Autism Diagnostic Observation Schedule (AD...